Peachtree
Provident Healthcare Partners (“Provident”), a leading healthcare investment banking firm, is pleased to announce it has advised Peachtree BioResearch Solutions (”Peachtree”), a U.S.-based, CNS-focused clinical research organization (“CRO”), in its strategic merger with Julius Clinical, a Netherlands-based full-service CRO and portfolio company of Ampersand Capital Partners. The merger creates a fully integrated, global clinical research organization with expanded capabilities across central nervous system (“CNS”), cardio-metabolic, renal, and rare diseases.
This transaction marks a significant milestone in Peachtree’s evolution and reflects the deep alignment between both companies’ cultures, scientific depth, and operational expertise. Together, the combined organization offers end-to-end Phase I-III clinical trial services across North America and Europe, with a robust footprint to better serve pharmaceutical, biotech, and medical device clients.
“This partnership with Julius Clinical is a tremendous outcome for Peachtree and a reflection of the incredible work our team has done over the years. Provident was instrumental throughout this process. Their deep understanding of the CRO landscape, strategic guidance, and steady partnership helped us navigate the complexities and ultimately align with the right long-term partner,” commented Kristy Nichols, Chief Executive Officer at Peachtree.
“Peachtree’s differentiated positioning in CNS research, coupled with its strong leadership and operational foundation, made this an incredibly compelling opportunity for a global partner like Julius Clinical. The alignment between both teams was clear from the outset, and we are proud to have advised Peachtree through this important milestone in their growth journey,” stated Dustin Thompson, Director at Provident.
The merger enables the combined CRO to address the growing demand for specialized, cross-border clinical research partners with the flexibility and scale to support both emerging biotech and mid-sized pharmaceutical programs.
“It was a privilege to work alongside the Peachtree team in a transaction that not only enhances their global reach but also strengthens their ability to serve clients with increasingly complex clinical programs,” commented Tommy Spiegel, Vice President at Provident. “This partnership creates a well-balanced CRO platform with the scale and specialization needed in today’s evolving research landscape.”
About Peachtree BioResearch Solutions
Founded in 2008, Peachtree BioResearch Solutions is a specialized CRO offering comprehensive clinical development services across project management, clinical monitoring, medical monitoring, biometrics, report writing, QA, and clinical staff resourcing. Peachtree has supported more than 65 clients, ranging from niche biotech programs to full-service engagements.
For more information, visit www.peachtreebrs.com.
About Julius Clinical
Julius Clinical is a full-service CRO based in Zeist, Netherlands, with deep expertise in CNS, cardio-metabolic, renal, and rare diseases. Since 2008, Julius Clinical has led more than 380 trials involving over 220,000 participants across 39 countries.
For more information, visit www.juliusclinical.com.
About Provident Healthcare Partners
Provident is a leading healthcare investment banking firm specializing in merger and acquisition advisory, strategic planning, and capital formation services for healthcare companies. The firm has a comprehensive knowledge of market sectors and specialties, including pharmaceutical services. Provident also has unsurpassed experience and insight into the M&A process, which includes working with a multitude of investors such as private equity firms and strategic consolidators. For additional information, visit www.providenthp.com or follow Provident on LinkedIn.
Contact: Provident Healthcare Partners
Rebecca Leiba
617-226-4209
rleiba@providenthp.com
